Last reviewed 2026-05-19 · How we verify

amlodipine 5mgs

Imperial College London · Phase 2 active Small molecule ✓ Verified May 2026

amlodipine 5mgs is a Small molecule drug developed by Imperial College London. It is currently in Phase 2 development.

Amlodipine 5mg is a small molecule that acts as a blocker of the voltage-gated L-type calcium channel. It has been studied in clinical trials, including one for the treatment of abdominal aortic aneurysm.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	amlodipine 5mgs
Sponsor	Imperial College London
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

AARDVARK (Aortic Aneurysmal Regression of Dilation: Value of ACE-Inhibition on RisK) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

amlodipine 5mgs CI brief — competitive landscape report
amlodipine 5mgs updates RSS · CI watch RSS
Imperial College London portfolio CI

Frequently asked questions about amlodipine 5mgs

What is amlodipine 5mgs?

amlodipine 5mgs is a Small molecule drug developed by Imperial College London.

Who makes amlodipine 5mgs?

amlodipine 5mgs is developed by Imperial College London (see full Imperial College London pipeline at /company/imperial-college-london).

What development phase is amlodipine 5mgs in?

amlodipine 5mgs is in Phase 2.

Manufacturer: Imperial College London — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing